Angela Koehler is not an engineer, yet her appointment is in the Department of Biological Engineering. Focused on so-called “undruggable” targets for cancer, Koehler’s training as a chemical biologist allows her to think creatively about how to find and deploy small molecules that intervene in transcriptional processes, including those that influence tumor formation and growth. Her approach has led to several promising drug candidates and spin-out companies.